WO2020111524A8 - 퓨로피리미딘 화합물의 염 및 결정형, 및 이의 약학적 용도 - Google Patents
퓨로피리미딘 화합물의 염 및 결정형, 및 이의 약학적 용도 Download PDFInfo
- Publication number
- WO2020111524A8 WO2020111524A8 PCT/KR2019/014164 KR2019014164W WO2020111524A8 WO 2020111524 A8 WO2020111524 A8 WO 2020111524A8 KR 2019014164 W KR2019014164 W KR 2019014164W WO 2020111524 A8 WO2020111524 A8 WO 2020111524A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- crystalline form
- pharmaceutical use
- compound
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021530802A JP2022510928A (ja) | 2018-11-30 | 2019-10-25 | フロピリミジン化合物の塩および結晶形ならびにその医薬用途 |
ES19889945T ES2952033T3 (es) | 2018-11-30 | 2019-10-25 | Sal y forma cristalina de un compuesto de furopirimidina y uso farmacéutico de estas |
US17/296,836 US20220002312A1 (en) | 2018-11-30 | 2019-10-25 | Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof |
EP19889945.2A EP3889157B1 (en) | 2018-11-30 | 2019-10-25 | Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof |
CN201980078178.9A CN113166172A (zh) | 2018-11-30 | 2019-10-25 | 嘌呤并嘧啶化合物的盐和晶型及其药物用途 |
CA3124684A CA3124684A1 (en) | 2018-11-30 | 2019-10-25 | Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180151990A KR101973074B1 (ko) | 2018-11-30 | 2018-11-30 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
KR10-2018-0151990 | 2018-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020111524A1 WO2020111524A1 (ko) | 2020-06-04 |
WO2020111524A8 true WO2020111524A8 (ko) | 2021-07-22 |
Family
ID=66281116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/014164 WO2020111524A1 (ko) | 2018-11-30 | 2019-10-25 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이의 약학적 용도 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220002312A1 (ko) |
EP (1) | EP3889157B1 (ko) |
JP (1) | JP2022510928A (ko) |
KR (1) | KR101973074B1 (ko) |
CN (1) | CN113166172A (ko) |
CA (1) | CA3124684A1 (ko) |
ES (1) | ES2952033T3 (ko) |
WO (1) | WO2020111524A1 (ko) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI225863B (en) * | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
WO2001029044A1 (en) * | 1999-10-15 | 2001-04-26 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US9034850B2 (en) * | 2009-11-20 | 2015-05-19 | Sk Chemicals Co., Ltd. | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same |
BR112014021331B1 (pt) * | 2012-02-28 | 2020-12-15 | Tiumbio Co., Ltd | Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses |
FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2018
- 2018-11-30 KR KR1020180151990A patent/KR101973074B1/ko active IP Right Grant
-
2019
- 2019-10-25 ES ES19889945T patent/ES2952033T3/es active Active
- 2019-10-25 US US17/296,836 patent/US20220002312A1/en active Pending
- 2019-10-25 WO PCT/KR2019/014164 patent/WO2020111524A1/ko unknown
- 2019-10-25 EP EP19889945.2A patent/EP3889157B1/en active Active
- 2019-10-25 CN CN201980078178.9A patent/CN113166172A/zh active Pending
- 2019-10-25 JP JP2021530802A patent/JP2022510928A/ja active Pending
- 2019-10-25 CA CA3124684A patent/CA3124684A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3889157A4 (en) | 2022-08-31 |
CN113166172A (zh) | 2021-07-23 |
EP3889157B1 (en) | 2023-07-26 |
EP3889157A1 (en) | 2021-10-06 |
KR101973074B1 (ko) | 2019-04-26 |
CA3124684A1 (en) | 2020-06-04 |
US20220002312A1 (en) | 2022-01-06 |
JP2022510928A (ja) | 2022-01-28 |
WO2020111524A1 (ko) | 2020-06-04 |
EP3889157C0 (en) | 2023-07-26 |
ES2952033T3 (es) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2397450A1 (en) | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
FR21C1010I2 (fr) | 2,4,di-(hetero-) arylamino (-oxy)-5 pyrimidines substitutees utilisees comme agents antineoplasiques | |
AU2003215753A1 (en) | Imidazopyridine derivatives as kinase inhibitors | |
HRP20161657T1 (hr) | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta | |
RU2435760C2 (ru) | 1н-хиназолин-2,4-дионы | |
ME01312B (me) | Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze | |
WO2004087677A3 (en) | Pyrimidin-4-one derivatives and their use as p38 kinase modulators | |
CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
NZ612041A (en) | Compounds and their use as bace inhibitors | |
WO2004000318A3 (en) | Certain amino-substituted monocycles as kinase modulators | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
NZ588830A (en) | Inhibitors of protein kinases | |
CA2344290A1 (en) | Quinazoline derivatives | |
JP2012501312A5 (ko) | ||
HRP20060286T3 (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
GEP20104964B (en) | 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof | |
WO2005118579A3 (en) | Thiazole derivatives as chemokine receptor antagonists | |
WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
WO2007020411A8 (en) | Amide derivatives | |
WO2007050510A3 (en) | Hiv integrase inhibitors | |
JP2007501210A5 (ko) | ||
MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
WO2020111524A8 (ko) | 퓨로피리미딘 화합물의 염 및 결정형, 및 이의 약학적 용도 | |
WO2002000166A3 (en) | New compounds useful as antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19889945 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3124684 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021530802 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019889945 Country of ref document: EP Effective date: 20210630 |